Spin-off company of the Masaryk University
Institute of Biostatistics and Analyses (IBA) is a spin-off company of the Masaryk University, with a share of ownership by the Masaryk University.
The company focuses mainly on the areas of project management of clinical research, real-world evidence (RWE) projects, organisation and management of clinical trials, particularly non-interventional clinical trials and health registries. This main activity is complemented with other services such as market access support, cost-effectiveness analysis, pharmacovigilance, analysis of clinical data, development of tailored software products and graphic design.
About us
Daniel Schwarz chaired this year's MEFANET conference, which took place in Košice on 7-8 November 2023.The latest knowledge and experience in the field of modern technologies and innovations in medical education were presented at the conference.
Last week, Daniel Schwarz attended the CZECRIN annual conference, which took place in St. Anne's University Hospital Brno. He was very interested in the interactive session dedicated to CTIS, expertly mediated by members of ethics committees from various institutions, as well as the discussion around decentralized clinical trials.
We have been a spin-off of Masaryk University Brno for almost 10 years and are proud to be recognized on the market as a well-established company providing CRO services and Data Management.
Quality management
Pharmacovigilance
Web studio
Real-world evidence/data
The Institute of Biostatistics and Analyses is an investigator of the project “Extending services portfolio of an information system for the data management in clinical research”. The project is supported by the OP EIC from the European Union funds.
Main objective of the project is the development of a platform for composition of information systems focused on data management and data mining in the field of pharmaceutical industry and life sciences. Offer of digital services based on a developed and validated information system will make reliable analytical models accessible to the companies for their decision-making and precise information sources for regulatory bodies. The project steps out of a laboratory environment of clinical trials and focuses on the evidence supported by real-world data.
